News Hub | News Direct

Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions

Benzinga

By Kyle Anthony, Benzinga Palatin Technologies (AMEX: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, received the first FDA approval for a melanocortin agent, for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, with its product, Vyleesi ® (bremelanotide injection) – and it has big plans for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i (viagra ®, cialis ® ) monotherapy The melanocortin system is a group of hormones, receptors and other molecules in the body that regulate various physiological processes, including skin pigmentation, appetite, energy balance and inflammation. For Palatin Technologies, the melanocortin system has been a source of innovation. The firm leverages its knowledge of the melanocortin system to design therapeutics that directly engage one of the body’s natural pathways to resolve harmful inflammation, providing a novel approach that allows affected tissue time to heal. The Mission Of Palatin Technologies Founded in 1986 by Dr. Carl Spana and other scientists with the initial aim of developing proprietary technologies and drug candidates for large markets with unmet needs, including cardiovascular disease and cancer, the firm has undergone a series of changes over the years. In the early 2000s, Palatin began focusing on the melanocortin system, particularly developing drugs that target melanocortin receptors. The company’s mission is to leverage its unique insight and expertise in the industry and the melanocortin system to develop groundbreaking therapeutics for inflammatory and autoimmune diseases, focusing on ocular conditions, plus obesity and sexual dysfunctions. Maximizing The Capabilities Of The Melanocortin System The melanocortin system is mediated by a family of five related receptors that are essential to the body’s control of inflammation, immune response, metabolism, steroid hormone production and sexual function. As mentioned previously, Palatin Technologies’ current focus is on the design and development of receptor-selective melanocortin agonists for inflammation and autoimmune conditions, with an emphasis on ocular diseases, plus obesity and sexual dysfunctions. Palatin Technologies’ therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse intestinal and ocular inflammation in animal models. Current ocular drugs can be limited by drawbacks such as inadequate efficacy, high discontinuation rates and delayed onset of action. These challenges result in a less-than-ideal treatment experience, causing frustration and driving the need for more effective solutions. Melanocortin receptors, which are found on the surface of various cells in the eye and within immune cells in ocular tissue, represent a promising target for melanocortin agonists to offer relief and healing for individuals suffering from ocular diseases. For inflammation and autoimmune diseases, current treatments – including steroids, immune modulators and biologics – largely work by broadly suppressing the immune response. However, these methods can weaken the body's overall immune function, leading to unwanted side effects and raising safety concerns. Melanocortin agonists offer the potential to resolve inflammation without these adverse effects and safety issues associated with immunosuppressants. Palatin Technologies: Success And Product Pipeline Though Vyleesi was Palatin Technologies' first commercial product, the company recently announced several program advancements: Patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity Topline Results Expected Q1 Calendar Year 2025 FDA Confirms Acceptability of Palatin’s Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) MELODY-2 & MELODY-3 Phase 3 Clinical Trials Targeted To Start Later This Calendar Year Topline Results Expected Q4 Calendar Year 2025 Treating Eye Related Diseases As referenced previously, Palatin is exploring using melanocortin agonists for age-related eye diseases. As detailed in the company’s corporate presentation, diseases such as dry eye disease, glaucoma and retinopathies are sizable target markets. Dry eye disease (DED) or keratoconjunctivitis is a multifactorial disorder of the tears and ocular surface. Symptoms include dryness, irritation, redness, discharge and blurred vision. Inflammation plays a prominent role in the development and amplification of the signs and symptoms of DED. According to research compiled by the company, the global market size for DED is estimated to be worth $7.0 billion in 2024, growing to $12.3 billion by 2032. Earlier this year, Palatin announced the phase 3 clinical results for its PL9643 melanocortin agonist treatment of DED. Regarding the findings, Carl Spana, Ph.D., President and CEO of Palatin, stated, “We are pleased that PL9643 treatment demonstrated excellent safety and tolerability data, including superior efficacy results compared to vehicle across multiple sign and symptom endpoints.” PL9643 represents an opportunity to bring relief to dry eye disease sufferers. According to Palatin, while DED is one of the most common ocular disorders, affecting an estimated 38 million people in the U.S., only about 18 million are diagnosed, and less than 10% of those diagnosed are treated with a prescription product. This shows the significant unmet medical need for an effective treatment with an excellent safety and tolerability profile. There is a sizable market opportunity for the other previously mentioned eye diseases: Palatin’s research states that the 2030 global market estimate for glaucoma is $11.52 billion, and the 2027 global market estimate for retinopathies is $27 billion. Palatin has ongoing melanocortin receptor programs for each disease to explore treatment methods. Treating Autoimmune Diseases There is also a growing opportunity to treat the underlying inflammation in autoimmune diseases that physicians commonly treat with broad immunosuppressants that potentially increase the risk of complications. Palatin Technologies, with an ongoing phase 2 clinical trial, is exploring how its treatments can tackle ulcerative colitis (UC), which the company says could benefit nearly 1 million people in the U.S. who suffer from an autoimmune disease that manifests as chronic inflammation of the colon. Palatin’s research states that the global ulcerative colitis market was estimated to be worth $5.5 billion in 2021 and is projected to be worth $8 billion by 2026. Palatin’s oral MCR1 agonist (PL8177) was developed to resolve inflammation directly in the colon, avoiding broad immunosuppression and adverse effects with its potent, selective compound. Palatin reports that two phase 1 studies have produced promising results – the first demonstrated the significant safety and tolerability of PL8177, while the second highlighted the value of an oral, delayed-release polymer formulation that can achieve local release without systemic absorption. PL8177 has advanced and is now being investigated in a phase 2 clinical trial. Treating Obesity Obesity represents a rising worldwide public health concern. Obesity is associated with an increased risk of overall mortality and serious health conditions, including high blood pressure, high cholesterol, type 2 diabetes, coronary heart disease, stroke and certain cancers. Obesity is associated with increased healthcare resource use and high economic burden. Safe and effective obesity treatments therefore remain a critical unmet need. In the United States, about 42% of adults live with obesity, and one out of five teens between the ages of 12-19 live with obesity, according to data compiled by Palatin. “The growth of GLP-1 agonists to treat obesity has been incredible and highly effective in the short run, but data shows that 67% of patients discontinue use due to side effects and a plateau effect in the first year, said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. “This often results in a rebound effect with patients gaining back significant weight. Our research coupled with emerging clinical data indicates that combining an MCR4 agonist with incretin therapeutics like tirzepatide may result in synergistic effects on weight loss allowing for increased weight loss at lower and better-tolerated doses.” Sexual Dysfunction Product Expansion And Product Development Milestones The success of Vyleesi, which was sold to Cosette Pharmaceuticals in December 2023 for $12 million upfront and up to $159 million in sales milestones, has established a precedent for success in the sexual dysfunction category for Palatin Technologies. Presently, the firm is looking to build on this success and is exploring a product for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i (viagra ®, cialis ® ) monotherapy. According to Palatin, over 30 million men in the U.S. suffer from ED, with approximately 35% of them being inadequately served by existing treatment options. Palatin believes that their MCR4 agonists can be a safe and effective treatment therapy for ED. Across Palatin’s product roadmap, several milestones are slated to occur in the latter half of 2024 or the first half of 2025. Regarding the second half of calendar year 2024, the company’s phase 2 obesity trial of an MCR4 agonist + GLP-1 will initiate enrollment (patient dosing has commenced), Melody-2 and Melody-3 phase 3 clinical trials for the treatment of DED will begin, and the phase 2 proof-of-concept interim data for PL8177 for ulcerative colitis is expected to readout. Regarding the first half of calendar year 2025, the company’s phase 2 obesity trial of an MCR4 agonist + GLP-1 topline results are expected, and the pharmacokinetics study for the clinical program with bremelanotide co-formulated with a PDE5i for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i monotherapy will start. A Vision For The Future For Millions Of Patients Overall, Palatin Technologies is actively expanding its clinical programs and progressing toward potential new therapies for patients with limited or ineffective treatment options. Melanocortin pathway therapies represent a promising and versatile approach to treating various conditions, with ongoing research and development expanding their potential applications. Palatin Technologies is at the forefront of this treatment approach, potentially helping reshape the medical landscape. For more information about Palatin Technologies, visit its website. Featured photo by Louis Reed on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 29, 2024 08:45 AM Eastern Daylight Time

Image

How This Silver Miner Beat Expectations In Its Recent Earnings Report – And What It Has Planned Next

Benzinga

By Meg Flippin, Benzinga Silver is shining bright this year, with prices up 21% in 2024. It recently hit an 11-year high, and experts are calling for more price increases. That hasn’t been lost on Silvercorp Metals Inc. (AMEX: SVM), the mining company headquartered in Vancouver, British Columbia. The company posted strong first-quarter fiscal 2025 results that it says beat Wall Street expectations, and positioned it for more growth. Silver investors like the metal because it offers diversification beyond stocks and bonds. It tends to increase in price during periods of low interest rates, and with analysts projecting Fed rate cuts, an uptick in silver prices is expected. Just like gold, silver is seen as a store of value. If the U.S. dollar ever devalued, silver could even potentially be used as a form of currency. There’s also a scarcity of it, which means the price has room to appreciate. Much of the silver mined has been used and isn’t recoverable. The global deficit of silver reached an all-time high in 2022 at 237.7 million ounces as the demand for silver rose 18%. Revenue Growing, Costs Declining Silver is Silvercorp’s bread and butter, accounting for 63% of its first-quarter revenue. The company also mines gold, lead, and zinc. For the fiscal first quarter, Silvercorp reported revenue of $72.2 million, up 20% year-over-year, driven by rising silver prices. “The results of this quarter reinforce why investors should own our shares, namely demonstrating that we provide leverage to higher silver prices through the response in our financial results,” said Silvercorp president Lon Shaver during the company’s quarterly results conference call. Silvercorp surpassed Wall Street’s expectations, reporting a net income of $21.9 million, or adjusted earnings of $0.12 per share, up from $9.2 million or $0.05 per share, in the same quarter last year. Analysts had expected the company to weigh in with earnings of $0.09-$0.11 per share. Raymond James also highlighted this strong performance, noting that Silvercorp’s EBITDA of $41 million significantly outperformed their estimate of $26 million, as well as the consensus estimate of $34 million. Cash flow provided by operating activities was $40 million, up 28% year-over-year. Silvercorp ended the quarter with $216 million in cash and short-term investments, another $108 million in equity investments, and zero debt. The company says its results are a testament to its ability to capitalize on market conditions and optimize operations for maximum profitability. Silvercorp’s ability to beat analyst targets on the earnings and cost fronts prompted analysts to reiterate their buy ratings on the stock, with bulls pointing to the strong showing in the quarter, disciplined cost management, healthy cash generations and near-term catalysts as reasons to like the stock. “We largely view the quarter as positive, as the results beat our estimates on the bottom line supported by higher-than-expected realized silver prices, gains on investments and favorable exchange rate movements during the quarter,” wrote Eight Capital in a recent research report. The firm has a buy rating on shares of Silvercorp. Expansion Mode In Full Swing Beyond beating fiscal first-quarter estimates, Silvercorp closed a key acquisition that may serve as a catalyst for the company. In late July, Silvercorp completed its acquisition of Adventus Mining Corporation, creating a geographically diversified mining company. With the acquisition, Silvercorp added the advanced El Domo Project and the exploration stage Condor Project, both located in Ecuador, to its portfolio. Analysts view the move as positive; “For El Domo, we believe it is likely SVM will outline development plans as well as potential improvements to the project which could provide an additional source of positive catalysts in the coming months,” stated Roth Capital in a recent research report. Another potential catalyst is the Mill No. 2 capacity expansion, on track and on budget to be completed by November, which will significantly boost production capacity, Silvercorp reports. The company forecasts the project will increase its total production capacity to around 5,000 tons per day. Silvercorp has accumulated a stockpile of ore ready for processing, and this expansion is expected to increase the company’s output, further driving revenue growth. With silver prices projected to continue rising, and Silvercorp expanding its operational capacity and geographic reach through a strategic acquisition, it could be well-positioned and may offer investors substantial exposure to silver’s likely continued growth. For more information on Silvercorp, please visit silvercorpmetals.com/welcome. Featured photo by Zlaťáky.cz on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 29, 2024 08:45 AM Eastern Daylight Time

Image

Monogram Orthopedics (NASDAQ: MGRM) Readies Commercialization Of Next-Gen Surgical Robot

Benzinga

By Gerelyn Terzo, Benzinga When most people think about robotics, they might envision movies like the popular science fiction film RoboCop. While the entertainment industry put robotics on the big screen, companies like Austin, Texas-based Monogram Orthopedics (NASDAQ: MGRM) are making robotics a reality in everyday life. Monogram is an AI-powered robotics company dedicated to improving human health, including an early specialization in orthopedic surgery. This summer, it has been inching closer to its vision for the commercialization of its surgical robot. According to Virtue Market Research, the orthopedic surgery robotic market was worth $6.8 billion as of 2022 and is predicted to be valued at $16 billion by 2030, reflecting a CAGR of 13%. Monogram could be strategically positioned to capitalize on this growth with its mBôs surgical robot, which it is readying for commercialization, mVision technology and underlying IP. Benzinga recently had the opportunity to sit down with two Monogram surgeons – Dr. Bobby Jamieson and Dr. Fabio Orozco – to discuss the company’s next-generation orthopedic implants harnessing a combination of 3D printing, robotics and pre-operative imaging. Monogram’s 3D Printing Tech Dr. Fabio Orozco, an orthopedic surgeon, runs a medical practice that specializes in hip and knee replacements, with all of his surgeries involving robotics. After completing his training at Thomas Jefferson University in Philadelphia, Pennsylvania, he started a practice in the Northeast that is exclusive to robotics. He told Benzinga he performs 1,000 hip and knee replacements each year. With a very high success rate, hip and knee replacements are a testament to the strong track record of orthopedic surgeons. However, Orozco looks forward to using Monogram’s surgical robots on a daily basis, for, he says, greater precision, better patient care and improved outcomes. “You start thinking about 0.5 millimeters and 0.5 degrees and being able to reproduce your plan exactly to reality in a patient. And then you start seeing rapid recoveries - patients don’t need six months to recover from surgery or don’t need physical therapy. That’s when you see the excitement. We are better when we use technology, and when we use Monogram technology, we continue to be better and better,” said Orozco. Dr. Orozco performs 100% of his surgeries using robotics technology, including approximately 1,000 knee and hip replacements each year. He has been using Monogram’s Mako robot for the past decade, noting that it’s his go-to solution for every hip and knee replacement surgery. Dr. Orozco believes that when Monogram’s next-gen mBôs technologies become a reality, they will take orthopedic surgeries to a different level. “When you bring Monogram to your table, it’s going to make a significant difference in the way that we practice orthopedics,” he said. Chief among the new features that surgeons are anticipating from Monogram is the 3D printing of implants, which replicates the structure of human organs and tissues and can be customized to a patient’s body. Additionally, Monogram says its technology introduces increased precision and ease of use that will simplify robotic surgery significantly. For his part, Dr. Bobby Jamieson has been involved in robotics for years, having studied under the tutelage of orthopedic robotics pioneer and IBM (NYSE: IBM) alum Bill Barger and recently relocated his practice from Northern California to Southern Utah. Jamieson specializes in hip and knee surgeries, completing some 650 of them each year. Upon FDA approval of Monogram’s surgical robot, Jamieson looks forward to introducing the company’s technology to his patients. “I’ve been able to watch Monogram go from zero to where it is today and this is definitely something I’m interested in bringing into the practice once we get the approval on it,” Jamieson said. He also agreed that Monogram is taking orthopedic surgery to the next level. He said that what he appreciates most about the company’s technology is that it takes the best of all robotic platforms available, including features such as navigation, and builds them into a single robot, setting the tech suite apart and drumming up excitement in the industry. Monogram’s Competitive Edge With a market cap of over $90 million, Monogram’s advantage begins with its seasoned team and their strong robotics knowledge. The company’s singular focus on surgical robotic systems can give it a competitive edge against larger corporations that have a broader focus. “Monogram Orthopedics has the advantage is – they eat, drink and sleep robotics, which is awesome,” Jamieson said. “Then you add in 3D printing, and it just allows them to be a little bit further advanced than other surgical robots that are on the market right now.” He compares the precision of Monogram’s surgical robot to that of a driver in a golf game, saying that the tech helps surgeons hit the right spot every time with the ultimate patient-specific knee or hip replacement. That is what Monogram’s robot will deliver, and on top of that, there’s excitement around implants and being able to create the ultimate patient-specific knee or hip replacement for patients, where Monogram is also leading the charge. As Monogram transitions from gen-one to gen-two with its technology. Jamieson likens it to the iPhone, saying that most people wouldn’t even know how to access the first-generation iPhone model today because it’s just so obsolete. “I think that a lot of the robotics are those gen ones. The advantage that Monogram has coming to market is that it’s already at this iPhone five or 10 [level]… they’re able to come in as the newest technology that’s on the market and put it into one robotics system.” In the most recent update, Monogram Orthopedics submitted its 510(k) for its mBôs TKA System to the U.S. Food and Drug Administration (FDA) and has since received administrative approval to proceed with the next step, which involves a formal review. FDA approval is key for orthopedic surgeons to take Monogram’s surgical robots further, including the advancement of the technology on the clinical side. After that, they can begin using it in practice. “It’s an exciting time. It’s also obviously one of the most difficult steps, making sure all the “t’s” are crossed and all the “i’s” are dotted and, for that matter, making sure it’s safe for patients. And so it’s really important and also just exciting,” said Jamieson. Investors who are interested in the future of surgical robotics can learn more about the investment opportunities that Monogram Orthopedics has to offer here. Featured photo by PublicDomainPictures on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 29, 2024 08:30 AM Eastern Daylight Time

Image

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Global Markets News

Nuvectis Pharma (NASDAQ: NVCT) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation for its lead candidate, NXP800. This designation, specifically for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers, marks a critical step forward in Nuvectis’s mission to address unmet needs in oncology. Orphan Drug Designation: A Strategic Advantage The FDA’s Orphan Drug Designation is awarded to drugs that show promise in treating rare diseases affecting fewer than 200,000 people in the U.S. For Nuvectis, this designation not only validates the potential of NXP800 but also provides several strategic benefits. These include tax credits for clinical trial costs, exemption from certain FDA fees, and potentially seven years of market exclusivity upon approval. NXP800 targets ARID1a-deficient cancers, a subset of ovarian cancers that present significant treatment challenges. The Orphan Drug Designation underscores the importance of this candidate in potentially offering a new, more effective treatment option for patients with this specific genetic mutation. Background and Market Impact This latest achievement builds on Nuvectis Pharma’s earlier successes. Earlier this year, the FDA granted Fast Track Designation to NXP800 for its development in platinum-resistant, ARID1a-mutated ovarian cancer. The Fast Track status, combined with the Orphan Drug Designation, highlights the urgent need for innovative treatments in this space and positions NXP800 as a potential game-changer in oncology. Financial analysts have taken note of Nuvectis’s progress. H.C. Wainwright recently reiterated its buy rating for Nuvectis, setting a price target of $21. This optimistic outlook reflects the market’s confidence in the company’s strategic direction, particularly as it prepares to release key clinical data later this year. Anticipation for Upcoming Results The next few months are expected to be pivotal for Nuvectis Pharma. The company is poised to share updates from its ongoing Phase 1b clinical trial of NXP800, which targets patients with platinum-resistant, ARID1a-mutated ovarian cancer. This trial is being closely watched, as positive results could significantly advance the development of NXP800, bringing it closer to pivotal trials and eventual regulatory approval. Additionally, Nuvectis is also conducting a Phase 1a dose escalation study for NXP900, its second key candidate, which targets YES1/SRC-driven tumors. Updates from this study are expected to provide further insights into the safety and potential efficacy of NXP900. ### Nuvvectis' Full announcment, titled " Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers" was published on August 29th, 2024. ### This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. https://justpaste.it/fcm9n/pdf. Global Markets News Network is a commercial digital brand compensated to provide coverage of innovative companies and industries and it is thus subject to conflicts of interest. Contact Details Global Markets News News Coverage ronald@futuremarketsresearch.com

August 29, 2024 08:20 AM Eastern Daylight Time

News Release

Railtown AI Technologies (CSE: RAIL) (OTCQB: RLAIF): Leveraging AI to Revolutionize Software Development Efficiency

Railtown AI

The global artificial intelligence (AI) market was estimated at $196.63 billion in 2023 and is expected to grow at a staggering compound annual growth rate (CAGR) of 36.6% from 2024 to 2030, according to Grand View Research. Once seen as the stuff of science fiction, AI has steadily integrated into our daily lives, evolving from a buzzword to a household presence. More importantly, AI is now a cornerstone of modern business, driving efficiencies, cutting costs, and enabling companies to compete in an increasingly digital world. Businesses are harnessing AI in various ways: enhancing cybersecurity, managing fraud, crafting content, and improving customer relationships. A Forbes survey reveals that over half of business owners use AI for cybersecurity, nearly half use it for internal communications, and 64% believe it will strengthen customer relationships. Additionally, 97% of business owners see AI tools like ChatGPT as beneficial to their operations, with many planning to use AI for website content and multilingual communication. Investing in AI stocks has surged as companies across sectors leverage advanced AI technologies to boost productivity and enhance decision-making. This shift is expected to drive revenue and earnings growth in the coming years. With that in mind, it could be the right time to start looking into AI stocks. Now, let’s look at a rising company in this competitive sector. Railtown AI Technologies (CSE: RAIL) (OTCQB: RLAIF) is emerging as a promising player in the AI sector, offering innovative solutions that streamline software development. As a Microsoft Partner, Railtown AI has developed a cloud-based Application General Intelligence (AGI) platform designed to support software developers and Agile teams. The company’s primary focus is to save time on repetitive tasks, improve productivity, reduce costs, and accelerate developer velocity. This platform is readily accessible via Microsoft's Azure Marketplace, making it easily available to a broad range of businesses. What Railtown AI Technologies Does Railtown AI ’s proprietary platform is entirely owned and developed in-house, ensuring that the company has complete control over its technology. The platform is particularly notable for its dual deployment options, catering to organizations with different needs by offering both cloud-based and on-premise solutions. This flexibility, combined with the platform’s ability to process data quickly and learn over time, allows businesses to make real-time decisions and continuously improve their software development processes. The platform’s AI-driven tools target key areas in software development, offering significant benefits. The Root Cause Analyzer detects and alerts developers to errors early, allowing them to resolve issues before they affect users, thereby saving valuable time and reducing costs. The Conductor AI Assistant provides developers with quick, accurate information to solve problems faster, continuously learning from developer feedback to improve its capabilities. The Velocity Dashboard tracks the performance of development teams, helping management make informed decisions on resource allocation and performance management. Additionally, tools like the Release Notes Automator and Ticket Generator automate traditionally manual tasks, further boosting productivity and enabling teams to focus on more strategic work. Why It Matters In a world where software development is increasingly complex and fast-paced, the ability to streamline processes and reduce manual work is critical. Railtown AI’s platform addresses this need by offering tools that not only enhance developer productivity but also ensure higher-quality software. This is particularly important as the industry moves towards Agile practices, which prioritize quick iterations and continuous improvement. By enabling faster and more accurate development cycles, Railtown AI helps organizations stay competitive in a rapidly evolving market. Moreover, Railtown AI's focus on compliance with industry standards such as SOC 2, GDPR, and ISO 27001 is a significant advantage. These compliance achievements build customer trust by ensuring that the platform handles data responsibly and securely. In industries like finance and healthcare, where data protection is paramount, this compliance is not just a nice-to-have but a necessity. As Railtown AI continues to meet these standards, it positions itself as a trustworthy partner for businesses looking to integrate AI into their software processes. The Potential of Railtown AI Technologies Railtown AI has achieved several milestones that indicate its potential for growth. The company recently announced its debt-free status, strengthened its capital base through private placements, and made significant progress in meeting compliance requirements. These achievements, combined with strategic partnerships with leading institutions like the Mila Quebec AI Institute and Amii Alberta Machine Learning Institute, set the stage for future growth. These partnerships are particularly noteworthy as they provide Railtown AI with access to cutting-edge research and development support. For instance, Mila covers 90% of project costs for its research phase with Railtown, while Amii covers 50% of project costs. This financial support, coupled with expertise from PhD candidates and machine learning engineers, enhances Railtown AI ’s ability to innovate and improve its platform. Looking ahead, Railtown AI is poised to capitalize on its compliance achievements by investing in customer acquisition, marketing, and direct sales. The company’s plans to update its patents and explore certification as a vendor for major brands further bolster its growth prospects. As Railtown AI Technologies continues to enhance its platform and expand its market presence, its strategic innovations and strong growth potential make it a compelling stock to watch in the rapidly evolving AI sector. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com

August 29, 2024 06:00 AM Eastern Daylight Time

Munich-based deep tech Start-up Xplain Data named IDC Innovator for Industrial AI Applications and Solutions, 2024

Xplain Data GmbH

Munich, August 28, 2024 (ThriveNewsWire ) – Xplain Data GmbH, a pioneer in Causal AI, has been named IDC Innovator in the IDC Innovators: “Industrial AI Applications and Solutions, 2024” Report. (Doc # EUR252446124, August 2024) The IDC Innovator report highlights emerging vendors offer a new technology, a groundbreaking solution to an existing issue, and/or an innovative business model. Xplain Data GmbH is one of three vendors included in the report. Xplain Data's groundbreaking Causal AI solutions empower businesses to uncover critical, hidden causal relationships within their real-world production data. AI-powered Root Cause Analysis for Production Optimization By autonomously pinpointing the root causes of critical manufacturing anomalies and failures in real-time to quality managers, Xplain Data helps businesses optimize production processes. Actionable insights into causal relationships in production data enable manufacturers to proactively prevent issues before they occur, resulting in reduced downtime, less scrap, and increased throughput. Xplain Data’s patented ObjectAnalytics data storage system is the foundation for integrating data from all production stages and diverse sources. By structuring data around business objects like the “produced part”, it creates a unified, object-centric view. This holistic approach enables Xplain Data’s Causal AI algorithms to analyze complete output data, providing a comprehensive 360° view for making evidence-based decisions and developing impactful interventions. Dr. Michael Haft, CEO and Founder of Xplain Data, commented, “Being recognized as an IDC Innovator is a tremendous honor. Our patented technologies and groundbreaking Causal AI methodologies continue to drive industry transformation, enabling organizations to make evidence-based decisions with unprecedented confidence to optimize production processes. We view this recognition as a validation of our decade-long commitment to revolutionizing the way companies extract value from their data.” Full Report (Paywall): https://www.idc.com/getdoc.jsp?containerId=EUR252446124 About Xplain Data Xplain Data is a Munich-based deep-tech pioneer revolutionizing how businesses extract value from their data. Our patented Causal AI technology unveils hidden cause-and-effect relationships buried beneath layers of correlation, empowering organizations to make evidence-based decisions with unprecedented confidence. By identifying the root causes of problems or the drivers of success, clients across engineering, manufacturing, and healthcare optimize operations, reduce errors, and achieve their business goals. Xplain Data GmbH, founded in 2015, is still 100% owned by the founding team of four experienced data and AI enthusiasts. About IDC Innovators An IDC Innovators report presents a set of vendors – under $100M in annual revenue at the time of selection – chosen by an IDC analyst within a specific market that offers a new technology, a groundbreaking solution to an existing issue, and/or an innovative business model. It is not an exhaustive evaluation or a comparative ranking of all companies, but rather a document highlighting innovative companies in a specific market segment. IDC INNOVATOR and IDC INNOVATORS are trademarks of International Data Group, Inc. Contact Details Xplain Data Monika Roy Monika.Roy@xplain-data.com

August 28, 2024 12:12 PM Eastern Daylight Time

News Release

Lado Okhotnikov, CEO of Meta Force gave an interview to Forbes France regarding new business areas

Cartel Blue, Inc

Forbes France has presented an article about new innovative projects of Meta Force company. Meta Force until now was known as a developer of the sophisticated DeFi platform and Neo Dao metaverse, with more than two million users, so work in biology and medicine was quite surprising. Lado Okhotnikov on holistic approach Meta Force head Lado Okhotnikov has been interviewed by Forbes France and said about business diversification and development of new areas. One of these areas is the production of organic cosmetics and dietary supplements, based on holistic principles. The holistic principle considers the human body as a unique Universe with an infinite number of interconnected objects. Drugs, dietary supplements, physical exercises should be applied taking into account both internal and external factors such as physiological, psychological, social ones. This approach dramatically increases the efficiency of dietary supplements or therapies and gives cosmetics special health-enhancing properties. Lado Okhotnikov announced a new cosmetics line called Holisthetic. Unique soaps, shampoos, balms, creams will come out into the market soon. DNA and Metaverses Meta Force proposed an innovative approach involving the use of DNA technologies in the metaverses. One of the basic elements of a metaverse is the user’s avatar, “traditional” avatars have limited customization options. Usually, it is the visual characteristics and a functional simulating physical characteristics such as strength, speed, endurance etc. Meta Force has developed technologies of digitalizing the user’s DNA data and has integrated it into the avatar. Thus, the avatar becomes a full-fledged “digital” clone. In this case, the user gets a unique simulator on which you can test drugs, diet, exercise etc. Avatar will help you to find the best drug, minimize side effects, and predict health trends. This approach corresponds as closely as possible to the principle declared by Meta Force: “Virtual meets real”. Lado Okhotnikov, CEO of Meta Force will tell you more about the projects in the article. Forbes’ Gala dinner Forbes France traditionally organizes a Gala dinner, inviting promising companies and interesting projects. They are given the opportunity to present their projects to guests, among them there are top businessmen, politicians, sports, cinema and show business stars. Forbes France Gala dinner in July 2024 was entirely dedicated to the Meta Force projects. About company Meta Force is a company that develops the well-known digital platform and the Neo Dao metaverse. By August 2024, the number of users was more than two million. Today, the company announced its entry into new business areas related to biology and medical research. Lado Okhotnikov is a head and Founder of the company. He is an expert in IT, cryptocurrencies and blockchain, investor, publicist and prominent polemicist who advocates the interests of the crypto community. Based on Dan Michael’s materials The head of Meta Force Press Center press@meta-force.space Contact Details Meta Force Press Center Dan Michael +1 786-814-1818 press@meta-force.space Company Website https://meta-force.space/

August 28, 2024 11:30 AM Eastern Daylight Time

Benchmark International Unveils the 2024 Global HVAC Industry Report

Benchmark International

Benchmark International, a leader in the mergers and acquisition (M&A) industry, is proud to announce the release of its 2024 Construction Spotlight: Global HVAC Industry Report. The comprehensive report provides valuable insights into the heating, ventilation, and air conditioning (HVAC) sector, examining the latest trends, challenges, and opportunities shaping the industry worldwide. The report underscores the pivotal role the HVAC industry plays in the construction sector, driven by advancements in technology, increasing demand for energy-efficient solutions, and evolving regulatory requirements. As construction activity remains strong across various regions, the demand for innovative HVAC systems continues to grow, positioning the sector for significant expansion in the coming years. Key findings from the report include: Market Expansion: The global HVAC industry is experiencing significant growth, fueled by rising demand for energy-efficient systems and increasing construction activities across various sectors. Technological Innovations: Advancements in HVAC technology, including smart HVAC systems, IoT integration, and AI-driven solutions, are transforming the industry and driving efficiency improvements. Regulatory Influence: Stringent environmental and energy efficiency regulations are shaping the HVAC industry, prompting companies to adopt more sustainable practices and innovative solutions. Benchmark International’s report serves as an essential resource for construction companies, HVAC manufacturers, investors, and other industry participants, offering strategic insights to navigate the evolving landscape and stay ahead of the competition. The report is now available on Benchmark International's website and is part of the firm’s ongoing efforts to provide comprehensive market intelligence to its clients. For more information and to access the full 2024 Global HVAC Industry Report, please visit https://www.benchmarkintl.com/insights/2024-construction-spotlight-global-hvac-industry-report/ ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

August 28, 2024 09:35 AM Eastern Daylight Time

Image

How You Could Profit From The 2024 US Election With VantagePoint’s AI Software

Benzinga

By James Blacker, Benzinga U.S. stocks seem to be recovering following a recession scare in July that saw the S&P500 falling nearly 10% from its all-time high. The index has now risen almost 10% since the August 5 low, with the rebound partly driven by a series of economic reports this month on retail sales, inflation and producer prices, which have raised expectations that the Federal Reserve will cut interest rates later this year. However, with Vice President Kamala Harris set to square off against former president Donald Trump on November 5, analysts are warning that there could be more market turbulence yet to come, particularly with Harris leading in many polls after replacing President Joe Biden as the Democratic nominee. Election years typically bring volatility to global markets, and as election day looms, traders can expect to see intensifying fluctuations and shifts in investor sentiment. In fact, in a survey published by JPMorgan earlier this year, 20% of traders said they expected the election to be the biggest driver of stock movements this year. Why Elections Affect The Stock Market Presidential elections have wide-reaching ramifications for businesses and the economy, as they typically result in policy changes that can have a significant impact on various sectors. For instance, policy changes in healthcare can impact pharmaceutical stocks, while shifts in energy policy could affect oil and gas or renewables companies. Regulatory changes, fiscal policies, trade agreements and spending priorities can all be affected by election outcomes, creating both risks and opportunities for investors. Additionally, with so much uncertainty surrounding the future of the economy, global markets tend to be highly volatile as investors react to the latest polling data and presidential debates. This can potentially mean big price swings, making it crucial for traders to stay up to date with all the latest developments. During election periods, many traders tend to flock to commodities, indices and FX. In 2016, for example, after the UK’s referendum to leave the EU, the Germany Dax 40 index was the most traded instrument and the EUR-USD pair was the second most in demand instrument. How To Trade During Elections A golden rule for traders and investors is never to allow your own political views to inform your investing decisions. According to surveys conducted by the Pew Research Center, Democrat-aligned voters view the country’s economic condition as good under a Democratic president, while Republican-aligned voters rate the economy positively under a Republican president. This is despite the fact that average annual returns on the S&P500 were similar under both Obama and Trump, at 16.3% and 16%, respectively. Trading during an election year requires taking a strategic approach. With the right tools and strategies, investors can turn the heightened volatility into an opportunity to profit. Having access to reliable, real-time data and predictive analytics is crucial to making informed decisions. VantagePoint, a leader in A.I.-driven market forecasting software, can provide the insights needed to navigate the year of elections. Preparing For The 2024 Election With VantagePoint’s A.I. Software VantagePoint uses trained neural networks to provide traders with what it says are highly accurate, predictive forecasts of primary markets. These forecasts are based on intermarket analysis, meaning that the software compiles and analyzes data about the interconnectedness of global markets to detect hidden patterns that are undetectable by humans. Whereas traditional lagging indicators such as moving averages are simply a reaction to past price action, VantagePoint says its leading indicators can generate market predictions with up to 87.4% accuracy, and give you a head start on other traders. VantagePoint can also help you find exactly what to trade. There are thousands of securities to choose from, and it’s often the biggest decision you make as a trader. VantagePoint’s software helps you make asset selections, pinpointing the best stocks and options to trade. It even works with forex, crypto, futures and commodities. With VantagePoint's Intelliscan, you can quickly identify assets with a high potential to take off. The company says that this advanced scanning tool evaluates thousands of assets, highlighting the best stock and options opportunities. With clear, actionable insights, you can confidently target what to trade, armed with knowledge that helps you identify which stocks are likely to rise and which ones to avoid. This means you can potentially make smarter trades and maximize your time while minimizing effort. Traders and investors looking to get an edge in the markets during the election year could consider incorporating VantagePoint’s software into their trading strategies. With its A.I.-driven forecasts, traders can get a better understanding of future market movements and position themselves for success. VantagePoint is currently offering a free guide, called Electionomics 2024, which provides trading strategies that can maximize your profit during the election season using predictive artificial intelligence. For more information on VantagePoint, visit www.vantagepointsoftware.com. Featured photo by Tumisu from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 28, 2024 09:15 AM Eastern Daylight Time

Image

All Industries

Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions

How This Silver Miner Beat Expectations In Its Recent Earnings Report – And What It Has Planned Next

Monogram Orthopedics (NASDAQ: MGRM) Readies Commercialization Of Next-Gen Surgical Robot

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Railtown AI Technologies (CSE: RAIL) (OTCQB: RLAIF): Leveraging AI to Revolutionize Software Development Efficiency

Munich-based deep tech Start-up Xplain Data named IDC Innovator for Industrial AI Applications and Solutions, 2024

Lado Okhotnikov, CEO of Meta Force gave an interview to Forbes France regarding new business areas

Benchmark International Unveils the 2024 Global HVAC Industry Report

How You Could Profit From The 2024 US Election With VantagePoint’s AI Software